Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with:

  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat metastatic disease.
  • Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

As per global data analytics, global annual sales volumes of Eribulin Mesylate were at $392 million, including $153 million from the US, $126 million from Europe, and $112 million from the rest of the world. As of February 2022, Eribulin Mesylate (Halaven®) is approved in 39 countries worldwide.

To know more about our API offerings, please read the technical sheet on Eribulin Mesylate by filling the contact from below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.